Segundas hipotecas disparam com alta dos preços das casas

[Elias]

Boas AC,

Quando vejo um índice sectorial a subir alarvemente gosto de ir chafurdar para ver se percebo se se tratou de um movimento colectivo das acções que o compõem ou se houve alguma situação anormal.

Neste caso parece que houve uma situação anormal: uma das empresas que compõe o índice (ITMN) subiu 144%, contribuindo de forma decisiva para a subida de mais de 7% nesse dia.

Curiosamente não se tratou de uma OPA nem nada do género, foi apenas isto:

InterMune Shoots To The Moon
MarketNewsVideo.com , 12.17.10, 01:02 PM EST

InterMune is up 130% midday Friday after good news out of Europe on its drug to treat a fatal lung disease.

InterMune shares are surging Friday after an advisory committee to European regulators gave a positive opinion recommending approval of its drug Esbriet.

The drug is a treatment for idiopathic pulmonary fibrosis, a progressive and fatal lung disease. InterMune ( ITMN - news - people ) said the committees positive option will be forwarded to the European Commission for final approval, which typically occurs in two to three months.

InterMune said it is preparing for a commercial launch of the drug in Europe.

In other pharma news, Gilead Sciences ( GILD - news - people ) said late yesterday that the Department of Justice has said it has decided not to intervene in a False Claims Act lawsuit filed by a former employee of CV Therapeutics ( CVTX - news - people ), which Gilead acquired in 2009. The lawsuit was filed regarding the promotion of the drug Ranexa.

forbes.com

Fica também a lista de componentes do índice:

[AC Investor Blog]

O breakout de 6ºfeira atirou as farmaceuticas para a ribalta e parece que a festa começou, dada a força do Indice que quebrou máximos anuais.

NYSE Arca Biotechnology Index : The NYSE Arca Biotechnology Index (BTK) is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics. The BTK Index was established with a benchmark value of 200.00 on October 18, 1991. The BTK Index is rebalanced quarterly based on closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent approximately equal weight in the index.